Description: Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I clinical study in patients with advanced malignancies as a monotherapy; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with solid tumors; and AZD2936, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase I/II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused primarily on myeloid targets. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.
Home Page: cgen.com
Azrieli Center
Holon,
5885849
Israel
Phone:
972 3 765 8585
Officers
| Name | Title |
|---|---|
| Dr. Anat Cohen-Dayag Ph.D. | CEO, Pres & Director |
| Dr. Oliver Froescheis Ph.D. | Sr. VP of Corp. & Bus. Devel. |
| Dr. Zurit Levine | Sr. VP of Technology Innovation |
| Dr. Henry Adewoye M.D. | Sr. VP & Chief Medical Officer |
| Mr. Alberto Sessa | Chief Financial Officer |
| Ms. Yvonne Naughton | Head of Investor Relations & Corp. Communications |
| Mr. Eran Ben Dor | Gen. Counsel & Corp. Sec. |
| Ms. Dorit Amitay | VP of HR |
| Dr. Yaron Turpaz M.B.A., Ph.D., MBA | Sr. VP & Sr. Advisor of Computational Discovery |
| Rivka Schwartz | VP Research and Discovery |
Exchange: TA
Country: IL : Israel
Currency: Israeli Agora (ILA)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.1262 |
| Price-to-Sales TTM: | 46.8928 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 73 |